[Maintenance chemotherapy for ovarian adenocarcinoma with carboquone: doses and side effects (author's transl)].
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000201:enzymology; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001389:Azirines / Q000008:administration & dosage*; D002225:Carbazilquinone / Q000008:administration & dosage* / Q000009:adverse effects; D003536:Cystadenocarcinoma / Q000188:drug therapy / Q000201:enzymology; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D011379:Prognosis
D001389:Azirines; D002225:Carbazilquinone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase